Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents

International Journal of Urology

Volumn 19, Issue 9, 2012, Pages 806-811

  Kitajima, Kazuhiro ^a   Maeda, Tetsuo ^a   Watanabe, Sanae ^a   Ueno, Yoshiko ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gadolinium based contrast agents; Glomerular filtration rate; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; STEROID; THALIDOMIDE;

ACUTE KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; COVALENT BOND; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUVA; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84865565051     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03042.x     Document Type: Review

References (29)

1. U.S. Food and Drug Administration. Important drug warning for gadolinium-based contrast agents. September 2007. U.S. Food and Drug Administration. [Cited 7 Mar 2012.] Available from URL: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM154532.pdf.
2. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
3. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch. Dermatol. 2003; 139: 903-6.
4. Grobner T. Gadolium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial. Transplant. 2006; 21: 1104-8.
5. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J. Am. Acad. Dermatol. 2007; 56: 21-6.
6. Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). ICNFDR. [Cited 7 Mar 2012.] Available from URL: http://www.icnfdr.org.
7. Sadowski EA, Bennett LK, Chan MR etal. Neprogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-57.
8. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerne. AJR Am. J. Roentgenol. 2007; 188: 586-92.
9. Collidge TA, Thomson PC, Mark PB etal. Gadolium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168-75.
10. Thomsen HS; for the European Society of Urogenital Radiology (ESUR). ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur. Radiol. 2007; 17: 2692-6.
11. European Society of Urogenital Radiology. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Vienna Austria. [Cited 30 Aug 2011.] Available from URL: http://www.esur.org/Nephrogenic_Fibrosis.39.0.html.
12. American College of Radiology. ACR manual on contrast media, version 7.0. 2010. [Cited 7 Mar 2012.] Available from URL: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual/FullManual.aspx#page=8.
13. Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv. Chronic Kidney Dis. 2011; 18: 188-98.
14. Prince MR, Zhang H, Morris M etal. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248: 807-16.
15. U.S. Food and Drug Administration. New warnings required on use of gadonium-based contrast agents. U.S. Food and Drug Administration, 9 September 2010. [Cited 7 Mar 2012.] Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225286.htm.
16. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001-2007. [Cited 7 Mar 2012.] Available from URL: http://www.icnfdr.org.
17. U.S. Food and Drug Administration. Information on gadolinium-containing contrast agents. [Cited 7 Mar 2012.] Available from URL: http://www.fda.gov/cder/drug/infopage/gcca/default/htm.
18. Altun E, Martin DR, Wertman R, Lugo-Somolions A, Fuller ER III, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009; 253: 689-96.
19. Wang Y, Alkasab T, Narin O etal. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260: 105-11.
20. Kallen AJ, Jhung MA, Cheng S etal. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am. J. Kidney Dis. 2008; 51: 966-75.
21. Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J. Urol. 2010; 183: 27-33.
22. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J. Am. Acad. Dermatol. 2011; 65: 1095-106.
23. Pieringer H, Schmekal B, Janko O, Biesenbach G. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol. Dial. Transplant. 2007; 22: 3094.
24. Introcaso CE, Hivnor C, Cowper S, Werth VP. Neprogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int. J. Dermatol. 2007; 46: 447-52.
25. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008; 58: 2543-8.
26. Okada S, Katagiri K, Kumazaki Y, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001; 42: 339-41.
27. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Diayzability of gadodiamide in hemodialysis patients. Radiat. Med. 2006; 24: 445-51.
28. Perazella MA. Neprogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin. J. Am. Soc. Nephrol. 2007; 2: 200-2.
29. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb. Mortal. Wkly Rep. 2007; 56: 137-41.